Genomic Health (GHDX) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Jefferies Raises price Target on Genomic Health (GHDX) Following Initial 2016 Outlook
February 11, 2016 10:05 AM ESTJefferies reiterated a Hold rating on Genomic Health Inc. (NASDAQ: GHDX), and raised the price target to $25.00 (from $24.00). Consistent with commentary last month, GHDX reiterated its 2016 revenue outlook ($328M mid-pt), which implies a sharp growth acceleration on the back of full-year contributions from recent... More
Piper Jaffray Cuts Price Target on Genomic Health (GHDX) After 4Q Reports In-Line with Preliminary Results
February 11, 2016 9:15 AM ESTPiper Jaffray reiterated a Neutral rating on Genomic Health Inc. (NASDAQ: GHDX), and cut the price target to $31.00 (from $32.00), following the company's 4Q earnings report. Genomic Health announced 4Q15 revenue growth of 7.8% yoy to $74.5M, slightly above preliminary results ($73M-$74M). Management attributes... More



